Richard Harris

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.

In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington Star in DC.

Harris is co-founder of the Washington, DC, Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

Harris' book Rigor Mortis was published in 2017. The book covers the biomedicine "reproducibility crisis" — many studies can't be reproduced in other labs, often due to lack of rigor, hence the book's title. Rigor Mortis was a finalist for the 2018 National Academy of Sciences/Keck Communication Award.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Tonight, President Trump tried to quell rising fears about the effects of the growing coronavirus outbreak.

(SOUNDBITE OF ARCHIVED RECORDING)

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Despite worrisome new outbreaks in Iran, Italy and South Korea, the coronavirus disease called COVID-19 is not currently a pandemic, the World Health Organization said today.

In fact, there are some encouraging trends, especially in Hubei province, where most of the cases have been reported.

The epidemic there appears to have plateaued in late January and is continuing on a good trajectory. Dr. Bruce Aylward led a WHO trip to China with a scientific delegation that just concluded. On Sunday, he told reporters in Beijing that trend is real.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Even though the coronavirus disease that has sickened tens of thousands of people in China is new to science, doctors have a pretty good idea about how to treat it. COVID-19, as it is now named, attacks the lungs. Doctors see similar symptoms from other diseases all the time, especially from serious cases of the flu.

Updated at 5:01 p.m. ET

Last week, we asked our audience to share questions they might have about Wuhan coronavirus, the new respiratory virus that was identified in China.

While there is a lot we don't know about the virus — how the disease first emerged, for example — there are things that we do know.

China has reported a large surge of cases of the novel coronavirus — upping its count from under 3,000 to over 4,500 as of Tuesday morning. More than 100 deaths have been reported. It is spreading rapidly in many provinces, and sporadic cases have now been reported in 18 other locations outside of China, including Australia, France and Canada.

Hope for an effective and inexpensive treatment for the deadly condition sepsis has dimmed following results of a major new study.

Researchers had hoped that a simple treatment involving infusions of vitamin C, vitamin B1 and steroids would work against a disease that kills an estimated 270,000 people each year in the United States and 11 million globally. Sepsis, or blood poisoning, occurs when the body overreacts to infection. It leads to leaky blood vessels, which can cause multiple organ failure.

A medical condition that often escapes public notice may be involved in 20% of deaths worldwide, according to a new study.

The disease is sepsis — sometimes called blood poisoning. It arises when the body overreacts to an infection. Blood vessels throughout the body become leaky, triggering multiple-organ failure.

Cancer death rates in the United States took their sharpest drop on record between 2016 and 2017, according to an analysis by the American Cancer Society.

Cancer death rates in the U.S. have been falling gradually for about three decades, typically about 1.5% a year. But during the latest study period, the cancer mortality rate dropped 2.2%, "the biggest single-year drop ever," says Rebecca Siegel, scientific director for surveillance research at the cancer society.

Pages